Detecting a therapeutic cell
The present invention relates to a method of detecting a therapeutic cell expressing a dopamine transporter (DAT) at a central nervous system (CNS) site in a subject, which comprises the administration of a DAT tracer to the subject, wherein the presence of a therapeutic cell which expresses the DAT is determined.
1. A method of detecting a therapeutic cell expressing a dopamine transporter (DAT) at a central nervous system (CNS) site in a subject comprising the therapeutic cell, which method comprises the administration of a DAT tracer to the subject, wherein the presence of a therapeutic cell which expresses the DAT is determined by binding of the DAT tracer to the DAT on the therapeutic cell, and wherein the therapeutic cell is an immune effector cell engineered to express a DAT protein prior to administration of said cell to the subject.
2. The method according to claim 1 which comprises the steps of;
i) administering the therapeutic cell engineered to express a DAT protein to the subject;
ii) administering a DAT tracer to the subject; and
iii) determining the presence of the therapeutic cell expressing the DAT at a site in the CNS of the subject by single-photon emission computed tomography (SPECT) or positron emission tomography (PET).
3. The method according to claim 1 wherein the DAT tracer is [ 123 I]-FP-CIT (Ioflupane; [I-123] N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) nortropane) or [ 18 F]-FP-CIT ([ 18 F] fluoropropyl-carbomethoxy-iodophenyl-nortropane).
4. The method according to claim 1 wherein the DAT comprises the sequence shown as SEQ ID NO: 1, 4, 5, 6, 7 or 8 or a variant thereof with at least 80% sequence identity.
5. The method according to claim 1 wherein the CNS site is in the brain of the subject.
6. The method according to claim 1 wherein the immune effector cell expresses a chimeric antigen receptor (CAR).